Daniel Morillo Giles

Médico adjunto
Specialty:
Hematology and hemotherapy
Serving specialties:
  • Hematología y Hemoterapia
E-mail: Daniel.morillo@quironsalud.es
Hospitals where he/she works:
  • Hospital Universitario Fundación Jiménez Díaz
Consultation: Oncohealth room 7 START Madrid-FJD early phase unit, room 8
Opening times: Th (from 09:00 to 15:00) M,Tu,X,F (frome 09:00 to 15:00)
General Information

Consultant Hematologist – Lymphoma Unit, University Hospital Fundación Jiménez Díaz, Madrid (2017–Present)
Clinical Investigator – Early Phase Clinical Trials Unit (START-Madrid FJD), University Hospital Fundación Jiménez Díaz, Madrid (2017–Present)

Experience
  • Consultant Hematologist – Lymphoma Unit, University Hospital Fundación Jiménez Díaz, Madrid (2017–Present)
  • Clinical Investigator – Early Phase Clinical Trials Unit (START-Madrid FJD), University Hospital Fundación Jiménez Díaz, Madrid (2017–Present)
  • Consultant Hematologist, University Hospital General de Villalba, Madrid (2014–2017)
  • Medical Residency – Hematology and Hemotherapy, University Hospital Puerta de Hierro, Madrid (2010–2014)
Degree
  • Degree in Medicine and Surgery, Complutense University of Madrid (2009)
  • Specialist in Hematology and Hemotherapy (2010–2014)
  • Master’s Degree in Lymphoid Neoplasms, University of Santiago de Compostela (2021)
  • Master’s Degree in Immuno-Oncology, University of Navarra (2020)
  • Master’s Degree in Clinical Investigation, Autonoma University of Madrid (2018)
  • Master’s Degree in Hematologic Diagnosis, University of Barcelona (2016).
Research and teaching

Research:

  • Principal Investigator in multiple early-phase clinical trials for lymphoproliferative syndromes, multiple myeloma, and leukemia.
  • Clinical Investigator in the international project T-cell Project 2.0 (2024).
  • Sub-investigator in the project: Comprehensive Molecular Study of Angioimmunoblastic T-cell Lymphoma, FIS Grant 2021.
  • Identification of methylation patterns of tumor suppressor genes acting as prognostic factors or predictors of treatment response in multiple myeloma. Implications of the methylation of these genes in relapse. Madrid Association of Hematology and Hemotherapy Research Grant, 2016.

Teaching:

  • Professor for the master degree ESAME, Pharmaceutical Business School

Publications

Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025 Apr;12(4):e269-e281. doi: 10.1016/S2352-3026(24)00385-5. Epub 2025 Mar 13. PMID: 40090350.

Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodríguez-Otero P, Avivi I, Quijano Cardé NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, and Mateos MV; RedirecTT-1 Investigators and Study Group. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536. PMID: 39778168.

Díaz de la Pinta FJ, Manso R, Betancor Fernández I, Morillo Giles D, Mollejo M, Rodriguez-Pinilla SM. Association of both BCL2 positive and negative follicular lymphoma to clasical Hodgkin lymphoma and/or gray zone lymphoma. Hum Pathol. 2024 Oct;152:105639. doi: 10.1016/j.humpath.2024.105639. Epub 2024 Aug 14. PMID: 39151736.

Frutos Díaz-Alejo J, Morillo-Giles D, Díaz de la Pinta FJ, Manso R, Rodríguez-Pinilla SM, Rodríguez M. New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis. Leuk Lymphoma. 2024 Dec;65(13):2056-2059. doi: 10.1080/10428194.2024.2390567. Epub 2024 Aug 15. PMID: 39148309.

Lopez-Garcia A, Macia E, Gomez-Talavera S, Castillo E, Morillo D, Tuñon J, Ibañez B, Cordoba R. Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines. Med Sci (Basel). 2024 Apr 24;12(2):23. doi: 10.3390/medsci12020023. PMID: 38804379; PMCID: PMC11130872.

Hormigo-Sanchez AI; Lopez-Garcia A; Mahillo-Fernandez I; Askari E; Morillo D; Perez-Saez MA; Riesco M; Urrutia C; Martinez-Peromingo FJ; Cordoba R; Gonzalez-Montalvo JI. Frailty assessment to individualize treatment in older patients with lymphoma. Eur Geriatr Med. 14 - (6), pp. 1393 - 1402. 12/2023.

Cordoba R; Lopez-Garcia A; Morillo D; Perez-Saenz MA; Askari E; Prieto RE; Castillo Bazan E; Llamas Sillero P; Herrero Gonzalez A; Short Apellaniz J; Del Olmo M; Arcos J. Feasibility of Telemedicine in the Management Strategy of Patients With Lymphoma Amid the COVID-19 Pandemic in Spain: Prospective Observational Study. JMIR Form Res.17 - 7, 17/11/2023.

Haque T; Cadenas FL; Xicoy B; Platzbecker U; Alfonso-Pierola A; Avivi I; Brunner AM; Chromik J; Morillo D; Patel MR; Falantes J; Leitch HA; Germing U; Preis M; Lenox L; Lauring J; Brown RJ; Kalota A; Mehta J; Pastore F; Gu J; Mistry P; Valcárcel D. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leukemia Research. 134:107390, 11/2023.

Carlos Santonja; Daniel Morillo-Giles; Elena Prieto-Pareja; Carlos Soto-de Ozaeta; Cristina Serrano-del Castillo; Rocío Salgado-Sánchez; Ana-Wu-Yang Yi-Shi; Rebeca Manso; Socorro María Rodríguez-Pinilla. Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman-Report of a Case with 9-Year Survival. Medicina. 59(9), pp. 1628. 08/09/2023.

Morillo D; Vega V; Moreno V. CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies. Oncotarget. 14, pp. 749 - 752. 07/08/2023.

Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023 Apr 27;141(17):2114-2126. doi: 10.1182/blood.2022017333. PMID: 36720090; PMCID: PMC10646782.

Haque T, Cadenas FL, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, Brunner AM, Chromik J, Morillo D, Patel MR, Falantes J, Leitch HA, Germing U, Preis M, Lenox L, Lauring J, Brown RJ, Kalota A, Mehta J, Pastore F, Gu J, Mistry P, Valcárcel D. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leuk Res. 2023 Nov;134:107390. doi: 10.1016/j.leukres.2023.107390. Epub 2023 Sep 20. PMID: 37776843.

Diamond JR; Boni V; Valencia R; Nowakowski G; Cordoba R; Morillo D; Genvresse I; Merz C; Boix O; Lim E; Moreno V. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clin Cancer Res. 28 - 7, pp. 1285 - 1293. 11/04/2022

Rodríguez-Pinilla SM; Salgado RN; Chamizo C; Santonja C; Stewart P; Carvajal N; McCafferty N; Manso R; Morillo D; Piris MÁ; González de Castro D. Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.European Journal of Haematology. 3 - (1), pp. 171 -174. 09/11/2021.

Stefania Infante M; Fernández-Cruz A; Núñez L; Carpio C; Jiménez-Ubieto A; López-Jiménez J; Vásquez L; Del Campo R; Romero S; Alonso C; Morillo D; Prat M; Luis Plana J; Villafuerte P; Bastidas G; Bocanegra A; Serna Á; De Nicolás R; Marquet J; Mas-Ochoa C; Cordoba R; García-Suárez J; Comai A; Martín X; Bastos-Oreiro M; Seri C; Navarro-Matilla B; López-Guillermo A; Martínez-López J; Ángel Hernández-Rivas J; Ruiz-Camps I; Grande C. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer Medicine. 10 - (21), pp. 7629 - 7640. 11/2021.

Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA. An analysis of genetic targets for guiding clinical management of follicular lymphoma. Expert Rev Hematol. 13 - 12, pp. 1361 - 1372. 13/12/2020.


Awards and certifications

Member of the Spanish Society of Hematology and Hemotherapy, Spanish Lymphoma Group, and Madrid Association of Hematology and Hemotherapy.